Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website. # Sera ## Sitemaps [XML Sitemap](https://www.sera.com/sitemap_index.xml): Includes all crawlable and indexable pages. ## Posts - [Cervical Length, fFN, and Serum Biomarkers: Comparing Preterm Birth Prediction Tools](https://www.sera.com/blog/uncategorized/cervical-length-ffn-and-serum-biomarkers-comparing-preterm-birth-prediction-tools/): Spontaneous preterm birth affects approximately 9.9% of pregnancies globally and remains the leading direct cause of neonatal mortality.1 In the United States alone, approximately 377,000 preterm births were recorded in 2023.2 Yet despite decades of research, no single prediction tool reliably identifies every woman at risk of delivering early. - [Understanding Preterm Birth: Causes, Consequences, and Prevention](https://www.sera.com/blog/preterm-birth-education/understanding-preterm-birth-causes-consequences-and-prevention/): Preterm birth, delivery before 37 weeks of gestation, remains one of the most significant challenges in women’s health. Despite advances in obstetric care, preterm birth rates have plateaued or risen in many regions, and current prevention strategies often fall short due to the complexity of underlying causes. This high-level overview summarizes what clinicians need to know today: the etiology of preterm birth, its public health impact, and why improved early identification of risk is emerging as a critical component of modern prenatal care. - [PRIME Trial Results: A New Evidence-Based Approach to Preterm Birth Risk Assessment](https://www.sera.com/blog/preterm-birth-education/prime-trial-results-a-new-evidence-based-approach-to-preterm-birth-risk-assessment/): The PRIME Study is a multicenter randomized controlled trial of over 5,000 clinically low-risk singleton pregnancies.1 The study evaluated the impact to moms and babies of screening with the PreTRM® Test, a mid-trimester blood test measuring IGFBP4 and SHBG biomarkers, paired with accessible, commonly used interventions.  Pregnancies identified as higher risk were offered targeted interventions and experienced significant improvements in things like gestational age at birth, neonatal hospital length of stay, neonatal morbidity, and NICU admissions when compared with standard care. PRIME provides peer-reviewed clinical evidence supporting biomarker-based risk stratification to improve neonatal outcomes. - [From Surviving Preterm Birth to Shaping Solutions: My “Why” for Joining This Company](https://www.sera.com/blog/pregnancy/from-surviving-preterm-birth-to-shaping-solutions-my-why-for-joining-this-company/): Imagine trying to have a baby for 9 years. Imagine finally conceiving that baby. Imagine being admitted to the hospital during week 20 and being put on total bedrest in an effort to stop your baby from arriving too soon. Imagine spending 27 days in that hospital bed with nurses coming in every 4 hours to see if there is still a heartbeat. Imagine day 28 resetting the count to the number of days you will spend visiting your baby in the NICU. Now, imagine being offered a simple blood test during your prenatal care that would assess your risk of this kind of experience for you and your baby - and being empowered to work with your health care provider to create a care plan to try and mitigate that risk. ## Pages - [PRIME](https://www.sera.com/prime/): Home - - [Blog](https://www.sera.com/blog/) - [Stylesheet](https://www.sera.com/stylesheet/): Headings: Lora and Montserrat - [The Pregnancy Company®](https://www.sera.com/the-pregnancy-company/): We are honored to take on the task of addressing the problem of preterm birth. To do so effectively, we know that our values must infuse every facet of our work. # Sera > Sera Prognostics is a women's health diagnostics company ("The Pregnancy Company") that develops blood-based biomarker tests to assess pregnancy risk. Its flagship product, the PreTRM® Test, predicts an individual patient's risk of spontaneous preterm delivery in asymptomatic singleton pregnancies via a single blood draw at 18–21 weeks gestation. ## Products - [PreTRM Test overview](https://www.sera.com/products/labor-risk-assessment/): Preterm labor risk assessment product page, with paths for payers, employers, providers, and moms. - [PreTRM Test details](https://www.sera.com/products/pretrm-test/): Detailed information on the PreTRM Test itself. ## The Pregnancy Company (Audience Pages) - [The Pregnancy Company](https://www.sera.com/the-pregnancy-company/): Sera's mission, vision, and operating values. - [PreTRM for Healthcare Providers](https://www.sera.com/the-pregnancy-company/prenatal-assessment/): How the test supports risk assessment in clinical practice. - [PreTRM for Payers](https://www.sera.com/the-pregnancy-company/prenatal-care-cost/): Health economics and cost impact of the test for payers. - [PreTRM for Employers](https://www.sera.com/the-pregnancy-company/prenatal-care-statistics/): Benefits of the test for employer-sponsored health plans. - [PreTRM for Moms](https://www.sera.com/the-pregnancy-company/prevent-preterm-labor/): Patient-facing information about the test and pregnancy risk. ## Research & Resources - [PRIME Study](https://www.sera.com/prime/): Landmark randomized controlled trial results on PreTRM-guided interventions and neonatal outcomes. - [Research and Innovation](https://www.sera.com/pregnancy-related-concerns/): Overview of Sera's scientific approach and pipeline of future biomarker tests. - [Publications](https://www.sera.com/pregnancy-related-concerns/healthy-pregnancy/): Peer-reviewed publications and clinical evidence related to the PreTRM Test. - [Newsroom](https://www.sera.com/pregnancy-related-concerns/newsroom/): Company news and media coverage. - [Blog](https://www.sera.com/blog/): Articles related to pregnancy health and company updates. - [Videos](https://www.pretrm.com/news-resources/videos/): Educational and promotional video content. ## About - [About / Leadership](https://www.sera.com/about/): Executive leadership team and key consultants. - [Careers](https://www.sera.com/about/prenatal-care-organizations-careers/): Open positions and information on working at Sera. - [Contact](https://www.sera.com/about/contact-us/): Contact information. - [Investors](https://investors.seraprognostics.com/): Investor relations site. ## Legal - [Privacy Policy](https://www.sera.com/privacy-policy/) - [Terms & Conditions](https://www.sera.com/terms-conditions/) - [Licenses](https://www.sera.com/licenses/)